Jim Cramer: Sell Gap, But Buy Google and These 3 Stocks

Jim Cramer made the following calls on October 1st, 2013. What do you think about his picks?

Gap Inc. (NYSE:GPS): Jim Cramer ranked this stock a Sell. Cramer previously ranked this stock a Buy on June 13, 2013. The stock’s 52-week high is $46.56, and its 52-week low is $29.84. Cramer said that he was scared of the company, noting that he was not as comfortable about the Back to School season as he should be. The company’s stock has been trending downward over the past two months.

GPS 20131002

Google Inc. (NASDAQ:GOOG): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on August 19, 2013. The stock’s 52-week high is $928.00, and its 52-week low is $636.00. Cramer expressed faith in Google, though he mentioned that he would rather play the stock with call options than with a straight up buy. In a piece of good news for the company, the antitrust commissioner for the European Union declared that he would be willing to settle with Google rather than take the company to court over charges of monopolistic practices in the European search markets, which are overwhelmingly controlled by Google.

GOOG 20131003

SPDR Gold Trust (NYSE:GLD): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on March 19, 2013. The stock’s 52-week high is $174.07, and its 52-week low is $114.68. Despite having been on the decline for the past year, Cramer was optimistic about SPDR Gold Trust. He has gotten behind the company when he believes that the time is right to include gold in a portfolio of investments.

GLD 20131002

Insys Therapeutics Inc. (NASDAQ:INSY): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on September 27, 2013. The stock’s 52-week high is $37.94, and its 52-week low is $6.55. Cramer reiterated his buy rating on Insys Therapeutics, a company that has seen its stock soar in recent months. Cramer noted that the biotech sector was a good place to be as other stocks may experience volatility due to uncertainty over the budget debate in Washington.

INSY 20131002

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on September 30, 2013. The stock’s 52-week high is $39.83, and its 52-week low is $7.56. Cramer was quick to rank Isis Pharmaceuticals a buy for the second time this week. Between the company’s performance over the last few months, its potential new products, and Cramer’s positive sentiments toward the biotech sector in general, he had nothing bad to say about Isis.

ISIS 20131002

Don’t Miss: Google & Apple Stand Up to Speak Against NSA Regulations.

More from The Cheat Sheet